FDA approves gene therapy to fix mutations that can lead to blindness
by Melissa Healy, Los Angeles Times
Dec 20, 2017
3 minutes
In a decision that accelerates a new era for gene therapy, the Food and Drug Administration on Tuesday approved a DNA-altering medication that can reverse an inherited form of progressive blindness.
The FDA's blessing makes Luxturna, a treatment for retinal dystrophy caused by a specific genetic mutation, the first gene therapy cleared for use in the U.S. to treat a genetic disease other than cancer.
Tuesday's announcement marks the third time in five months that the
You’re reading a preview, subscribe to read more.
Start your free 30 days